Literature DB >> 22260832

Lipiodol accumulation and transarterial chemoembolization efficacy for HCC patients.

Tsukasa Kawaguchi1, Kazuyoshi Ohkawa, Kazuho Imanaka, Chie Tamai, Natsuko Kawada, Kenji Ikezawa, Hiroyuki Uehara, Yasushi Itou, Katsuyuki Nakanishi, Kazuhiro Katayama.   

Abstract

BACKGROUND/AIMS: To elucidate the prognostic factors for hepatocellular carcinoma (HCC) patients treated with transarterial chemoembolization (TACE).
METHODOLOGY: We studied 85 TACE-treated HCC patients, including 117 lesions, who fulfilled the Milan criteria. The area of iodized poppy-seed oil (lipiodol) accumulation on CT immediately after TACE was classified into three groups, by comparing with the area of HCC detected by CT during hepatic arteriography; accumulation surrounding the HCC lesion (group I), accumulation involving the entire area of the HCC lesion (group II), and accumulation that covered a portion of the HCC lesion (group III).
RESULTS: Among 85 patients, the 1- and 2-year disease free survival (DFS) rates were 67% and 50% in group I, 49% and 29% in group II and 29% and 15% in group III. DFS rate was higher in group I than in groups II and III (p=0.016 and p<0.001). Difference in DFS by lipiodol accumulation pattern was evident in patients aged 75 or younger.
CONCLUSIONS: Lipiodol accumulation pattern as evaluated by CT immediately after TACE may be a powerful indicator of the therapeutic efficacy of TACE in HCC patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22260832     DOI: 10.5754/hge11258

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  7 in total

1.  Prognostic factors for survival after transarterial chemoembolization combined with microwave ablation for hepatocellular carcinoma.

Authors:  Jia-Yan Ni; Hong-Liang Sun; Yao-Ting Chen; Jiang-Hong Luo; Dong Chen; Xiong-Ying Jiang; Lin-Feng Xu
Journal:  World J Gastroenterol       Date:  2014-12-14       Impact factor: 5.742

2.  Response assessment methods for patients with hepatic metastasis from rare tumor primaries undergoing transarterial chemoembolization.

Authors:  Lucas C Adam; Lynn J Savic; Julius Chapiro; Brian Letzen; MingDe Lin; Christos Georgiades; Kelvin K Hong; Nariman Nezami
Journal:  Clin Imaging       Date:  2022-06-26       Impact factor: 2.420

Review 3.  Prognostic factors for hepatocellular carcinoma recurrence.

Authors:  Antonio Colecchia; Ramona Schiumerini; Alessandro Cucchetti; Matteo Cescon; Martina Taddia; Giovanni Marasco; Davide Festi
Journal:  World J Gastroenterol       Date:  2014-05-28       Impact factor: 5.742

4.  Comparison of the Efficacy and Prognostic Factors of Transarterial Chemoembolization Plus Microwave Ablation versus Transarterial Chemoembolization Alone in Patients with a Large Solitary or Multinodular Hepatocellular Carcinomas.

Authors:  Lin Zheng; Hai-Liang Li; Chen-Yang Guo; Su-Xia Luo
Journal:  Korean J Radiol       Date:  2018-02-22       Impact factor: 3.500

5.  Combination nivolumab with transcatheter arterial chemoembolization for clinical remission of small cell lung cancer: A case report.

Authors:  Ziwei Guo; Chao Meng; Xing Wei; Chuanhao Tang; Jun Liang
Journal:  Thorac Cancer       Date:  2018-03-02       Impact factor: 3.500

Review 6.  Combination of transcatheter arterial chemoembolization and portal vein embolization for patients with hepatocellular carcinoma: a review.

Authors:  Zhiying Shao; Xin Liu; Chanjuan Peng; Liping Wang; Dong Xu
Journal:  World J Surg Oncol       Date:  2021-10-01       Impact factor: 2.754

7.  Tumor vascularity and lipiodol deposition as early radiological markers for predicting risk of disease progression in patients with unresectable hepatocellular carcinoma after transarterial chemoembolization.

Authors:  Cheng-Shi Chen; Fang-Kun Li; Chen-Yang Guo; Jin-Cheng Xiao; Hong-Tao Hu; Hong-Tao Cheng; Lin Zheng; Deng-Wei Zong; Jun-Li Ma; Li Jiang; Hai-Liang Li
Journal:  Oncotarget       Date:  2016-02-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.